jc
jc

News Center

Check category
/
/
/
【Chest Heart Standing Committee】 Prof. Wei Wang: One-Stop Domestic Aortic Valve "J-Valve® Chevrole" appeared on AHA 2017, Satisfied with 1-year follow-up results

【Chest Heart Standing Committee】 Prof. Wei Wang: One-Stop Domestic Aortic Valve "J-Valve® Chevrole" appeared on AHA 2017, Satisfied with 1-year follow-up results

  • Categories:News Channel
  • Author:
  • Origin:
  • Time of issue:2017-11-21 13:10
  • Views:

(Summary description)

【Chest Heart Standing Committee】 Prof. Wei Wang: One-Stop Domestic Aortic Valve "J-Valve® Chevrole" appeared on AHA 2017, Satisfied with 1-year follow-up results

(Summary description)

  • Categories:News Channel
  • Author:
  • Origin:
  • Time of issue:2017-11-21 13:10
  • Views:
Information

C

 

  On November 12, at the AHA 2017 Scientific Annual Meeting, Professor Wang Wei, member of the Chinese Society of Thoracic and Cardiovascular Surgery Branch and Structural Fundamental Disease Center of Fuwai Hospital of Chinese Academy of Medical Sciences, on behalf of "J-Valve? Cheyenne China Trial, "which published the results of the one-year follow-up of the study.

  J-Valve? is one of the first self-inflating interventional valves in China to be officially licensed and licensed in China. It is not only suitable for patients with traditional aortic stenosis but also for patients with aortic valve insufficiency. J-Valve? is therefore called One-Stop Device for aortic valve disease.

  J-Valve? ChinaTrial included 107 patients with aortic stenosis or aortic regurgitation from Fu Wai Hospital, West China Hospital of Sichuan University and Zhongshan Hospital affiliated to Fudan University. The overall success rate of transcatheter closure of J-Valve? valve was 93.3%. The success rate was 95.2% in 43 patients with aortic valve insufficiency. Thirteen patients with high-risk aortic valve valve (BAV) Among patients, the success rate was 92.3%.

  The follow-up results at 30 days postoperatively showed that all the patients enrolled in this study had no postoperative stroke and coronary occlusion, the permanent implantation rate and the flap implantation rate were 3.7% and 0.9% respectively, Low level.

  At 1 year after the end of follow-up, overall mortality was only 5% in high-risk patients; cardiac function improved significantly in all patients with aortic valve stenosis and in 97% of patients with aortic regurgitation who had NYHA heart Functional grade Ⅰ ~ Ⅱ grade; quality of life scores were significantly improved in all patients; 74.2% of the patients did not have paravalvular leak or only a small amount of perivalvular leakage, no moderate-severe perivalvular leakage, permanent pacemaker implantation rate 5%.

  In addition, there was no significant difference between overall survival and no-major cardiovascular events in patients with aortic stenosis and aortic regurgitation.

  Professor Wang Wei said that the success of the J-Valve? Flaps? valve at 1 year follow-up was satisfactory. The success of the J-Valve? Flaps? valve is closely linked to several innovative features of the valve, such as valve displacement, detachment, and paravalvular leak Low risk. In contrast to published data from other major foreign interventional valves, the J-Valve? mitral valve is at a more advanced level in postoperative morbidity and hemodynamic parameters. Professor Wang Wei believes that domestic independent intellectual property equipment is expected to play an important role in the world's upsurge in the treatment of valvular diseases.

 

X

Contact us

这是描述信息

+86-512-63179788(WJ) | +86-512-63036288(SZ)

这是描述信息

Building4-1,Hi-Tech Park, Wujiang, Jiangsu Province, China

C21 Building, 218 Xinghu Street, Suzhou Industrial Park, China

这是描述信息

215200

FOLLOW US

这是描述信息

Mobile Website

这是描述信息

WeChat

Copyright ©  Suzhou Jiecheng Medical Technology Co., Ltd. 

这是描述信息